Taevas
Taevas Global identifies, vets, and connects life-sciences companies with compliant local manufacturing partners across 120+ markets so you can scale with confidence.
Local Manufacturer is Taevas Global's end-to-end service for identifying, evaluating, and onboarding in-country or regional manufacturing partners for pharmaceutical, medical device, personal care, and nutraceutical companies expanding into new markets. We combine deep regulatory knowledge, on-the-ground networks, and rigorous due diligence to ensure every partner we recommend meets your quality, compliance, and commercial requirements.
Unlike generic sourcing platforms, Taevas brings life-sciences-specific expertise to every engagement. Our team maps local Good Manufacturing Practice standards, import substitution incentives, technology transfer requirements, and capacity constraints before presenting a shortlist of vetted manufacturers — saving clients months of independent research and costly false starts.
The outcome: a board-ready manufacturer shortlist with full regulatory, financial, and operational due diligence completed.
We scan our proprietary database of 10,000+ life-sciences manufacturers across 120+ markets to surface candidates that match your product category, volume requirements, and quality standards.
Each candidate is screened against local GMP, import licensing, and product-specific registration requirements to ensure compliance before any commercial conversation begins.
We benchmark pricing, minimum order quantities, capacity utilization, and lead times so you enter negotiations with full market context and maximum leverage.
From term-sheet guidance to quality agreement templates and technology transfer planning, Taevas supports the full onboarding journey until production is live.
Every Local Manufacturer engagement is structured around six interconnected pillars that together ensure you select the right partner, at the right cost, with the right compliance posture.
We build a comprehensive map of the manufacturing ecosystem in your target market, including the number of licensed facilities, dominant players, capacity gaps, and emerging contract manufacturers. This landscape becomes the foundation for all subsequent shortlisting decisions.
Every candidate facility is assessed against national GMP standards, WHO prequalification status where relevant, and product-specific licensing requirements. We flag any remediation gaps and estimate the time and cost to close them before you commit.
Our team reviews audit histories, inspection reports, deviation logs, and quality management system documentation to give you an objective picture of each manufacturer's quality culture. We surface red flags that standard commercial due diligence routinely misses.
We provide detailed benchmarks on tolling fees, raw material sourcing practices, technology transfer costs, and typical contractual terms in each market. Clients enter negotiations informed, not exposed.
For companies pursuing multi-market manufacturing strategies, we map how a local manufacturer in one country can serve as a regional export hub, identifying mutual recognition agreements and free-trade-zone advantages that reduce overall manufacturing costs.
After partner selection, Taevas can provide periodic performance reviews, regulatory change alerts, and re-benchmarking services to ensure your manufacturing relationship remains competitive and compliant as market conditions evolve.
A structured four-stage process that balances speed with rigour — typically complete in 4–6 weeks.
We align on objectives, geographies, therapy areas, and the specific business questions that need answering.
A 30–45 minute scoping call establishes the intelligence framework — ensuring every subsequent research hour is focused on decisions that matter.
Taevas delivers Local Manufacturer services tailored to the distinct regulatory, quality, and commercial requirements of every major life-sciences sector.
From branded generics to biologics, we cover the full pharmaceutical value chain — clinical pipeline tracking, patent cliff analysis, and reimbursement modelling across regulated and emerging markets.
Our Local Manufacturer network spans every major life-sciences manufacturing hub and high-growth emerging market across six global regions.
India · China · Japan · South Korea · Australia · Indonesia · Thailand · Vietnam · Philippines
Germany · France · UK · Italy · Spain · Netherlands · Switzerland · Poland · Sweden
United States · Canada · Brazil · Mexico · Colombia · Argentina · Chile
UAE · Saudi Arabia · Turkey · Israel · Egypt · Qatar
South Africa · Nigeria · Kenya · Ethiopia · Morocco
Bangladesh · Sri Lanka · Pakistan · Nepal · Myanmar
Every Local Manufacturer engagement includes a comprehensive suite of research, analysis, and advisory deliverables designed to support decision-making at every stage.
TAM/SAM/SOM with 5-year projections, segmented by product type, end user, and geography.
Profiling of top 10–15 players with pipeline, financials, positioning, and SWOT analysis.
Step-by-step approval guide, typical timelines, required dossiers, and local partner requirements.
Benchmark pricing across channels, reimbursement eligibility, and HTA decision landscape.
Prioritised strategy with recommended partnerships, channels, and launch sequencing.
Key opinion leaders, payer organisations, and the distributor ecosystem across target markets.
Interactive data visualisation summarising findings for C-suite and board presentations.
Post-delivery support to clarify findings, run scenario analyses, or refine recommendations.
Local Manufacturer is designed for life-sciences leaders who need a trusted, expert partner to navigate the complexity of in-country production at speed.
Evaluating new market entry, product launches in new geographies, or acquisitions requiring deep commercial due diligence.
Conducting commercial due diligence, validating market size assumptions, or assessing competitive moats before committing capital.
Seeking investor-grade market data to underpin fundraising narratives, identify first-mover opportunities, or prioritise expansion.
Understanding sector landscapes, benchmarking policy environments, and identifying foreign investment opportunities in health and life sciences.
Translating academic research into commercial potential assessments, technology transfer opportunities, and licensing strategy.
White-label intelligence support for strategy and management consulting firms advising clients across life sciences markets.
Our analysts work exclusively in pharma, medtech, and consumer health. Every report reflects deep domain expertise — not generic research methodology applied to healthcare.
We don’t just aggregate public data. Every engagement includes primary interviews with regulators, KOLs, payers, and channel partners — intelligence you can’t Google.
Our network spans India, Southeast Asia, MENA, and Sub-Saharan Africa — markets that generic firms cover superficially but where the greatest growth opportunities exist.
We write for decision-makers, not archives. Every report includes a clear recommendation. Our readout sessions are structured for board discussions, not just information transfer.
Rapid-response turnarounds of 2–4 weeks for focused engagements — without sacrificing the rigour of primary research and expert validation.
Our 30-day Q&A window, ongoing subscriptions, and retainer models mean we’re a long-term intelligence partner — not a one-off vendor.
“Taevas reduced our manufacturer shortlisting timeline from four months to six weeks and gave us a level of regulatory and quality due diligence we simply could not have produced internally. We entered negotiations with complete confidence.”
Local Manufacturer is most powerful when combined with Taevas's broader suite of market entry, regulatory, and commercial intelligence services.
From regulatory pathway mapping to full dossier preparation and submission management across global markets.
Shortlisting, evaluating, and connecting you with validated in-market partners, distributors, and licensing candidates.
Optimise launch pricing, reimbursement positioning, and access pathways to maximise commercial success from day one.
Scientific communication strategy, publication planning, and structured KOL engagement programmes for new market entrants.
Investor-grade commercial assessments for M&A, licensing deals, or fundraising — with rapid turnaround for live transactions.
Monthly or quarterly market monitoring — competitive signals, regulatory updates, and commercial developments as a managed service.
Tell us your target market and product category and we will have a scoping call scheduled within 48 hours. Most clients receive their manufacturer shortlist within six weeks.